Key points are not available for this paper at this time.
The objective of this study was to analyse the prognosis values of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation on the overall survival in patients with newly diagnosed isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma multiforme (GBM). A retrospective observational study was conducted on 108 IDH1 wild-type glioblastoma patients who underwent tumour resection at neurosurgical centres, including Hanoi Medical University Hospital and Viet Duc University Hospital, from October 2017 to December 2021. The MGMT status was assessed using methylation-specific Polymerase Chain Reaction (MSP). Multivariable Cox proportional hazards models and Kaplan-Meier survival analysis were performed. Of 108 patients, 79.6% had methylated MGMT. The median overall survival of patients with IDH1 wild-type GBM was 8.47 months (95%Confidence Interval (CI) =6.93-11.07). Patients with Methylated MGMT had a lower mortality risk (Hazard Ratio (HR) =0.63, 95%CI=0.41-0.98) than those without Methylated MGMT. Patients aged =55 years old. Having tumours on both sides of the hemisphere was associated with a higher risk of mortality (HR=3.18, 95%CI=1.68-6.00) compared to patients with tumours on the right side of the hemisphere. To conclude, our data underline the impact of the MGMT promoter methylation status in the treatment response of IDH1-wildtype GBM. In addition, age, tumour size and hemisphere were also significant prognostic factors in the overall survival of patients.
Dang Viet Dung (Sat,) studied this question.